LONDON--(BUSINESS WIRE)--Oct. 2, 2017--
LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a
market-leading medical technology company, today announced its
system (ATS), XTRA®, has treated its one-millionth
patient at Houston Methodist Hospital in Houston.
This Smart News Release features multimedia. View the full release here:
LivaNova commemorates the one-millionth patient treated with its XTRA® autotransfusion system with the multidisciplinary blood management team at Houston Methodist Hospital. (Photo: Business Wire)
Used during and after surgical operations, XTRA is the innovative,
intuitive and powerful ATS system, a cost-effective solution that aims
to improve patient outcome by reducing the exposure to allogeneic
transfusions and the associated risks.
“With the decreasing worldwide availability of allogeneic blood and the
risks associated with its transfusion, there has been a shift in the
healthcare community to optimize the use of autotransfusion,” said
Kimberly Roy, a certified perioperative blood management technologist
with Houston Methodist Hospital, who treated the one-millionth patient.
“The implementation of a blood management strategy, especially with the
use of autotransfusion systems, has reduced the level of risks
associated with transfusion.”
The XTRA system provides the safe and effective collection, processing
and reinfusion of patient blood during surgery. Designed as an intuitive
and information-rich system, XTRA features advanced patient data
management capabilities and an accessible graphic touchscreen interface.
The system can be used during and after a range of surgical procedures,
including cardiac, high-bleeding or emergency operations, orthopedic and
“For more than three decades, LivaNova has developed and delivered
state-of-the-art autotransfusion solutions for patients,” said Brian
Duncan, M.D., LivaNova’s Vice President of Medical Affairs for the
Cardiac Surgery franchise. “We are proud to reach this milestone for the
innovative XTRA system. We look forward to continuing to address vital
needs of healthcare providers and hospitals for blood management
strategies during surgery.”
To learn more about XTRA and LivaNova’s portfolio of autotransfusion
solutions, please visit www.livanova.com.
LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London and with a presence in more than 100 countries worldwide, the
company employs more than 4,500 employees. LivaNova operates as three
business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola (Italy),
Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.LivaNova.com.
Safe Harbor Statement
Any forward-looking statements are subject to risks and uncertainties
such as those described in LivaNova’s periodic reports on file with the
Securities and Exchange Commission. Actual results may differ materially
from anticipated results.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171002005027/en/
Source: LivaNova PLC
LivaNova PLC Investor Relations and Media
Karen King, +1
Vice President, Investor Relations & Corporate
Deanna Wilke, +1 (281) 727-2764
External Communications Manager